Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0832 • ACR Convergence 2020
PROSARA – A Prospective, Multicenter, Noninterventional Study to Evaluate the Safety and Effectiveness of Sarilumab for the Treatment of Active Rheumatoid Arthritis in Regular Care in Germany
Eugen Feist¹, Peer-Malte Aries², Silke Zinke³, Harald Burkhardt⁴, Inka Albrecht⁵, Oliver Bley⁵, Michael Obermeier⁶, Patrizia Sternad⁷, Martin Welcker⁷, Cornelia Kühne⁸, Ann-Dörthe Holst⁹, Niklas Thomas Baerlecken¹⁰ and Hans-Peter Tony¹¹, ¹Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, ²Rheumatologie im Struenseehaus, Hamburg, Germany, ³Outpatient Rheumatology Center Berlin-Lichtenberg, Berlin, Germany, ⁴Department of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany, Frankfurt am Main, Germany, ⁵Sanofi Aventis Deutschland GmbH, Berlin, Germany, ⁶GKM Gesellschaft für Therapieforschung, Munich, Germany, ⁷MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany, ⁸Outpatient practice, Haldensleben, Germany, ⁹Outpatient practice, Ludwigslust, Germany, ¹⁰Rheumatology Cologne Dr. N. Baerlecken/Dr. T. Karger, Cologne, Germany, ¹¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany
Background/Purpose: Blockade of IL-6 signaling by sarilumab has been demonstrated to be an effective treatment approach for RA. Due to strict inclusion and exclusion criteria,…
Abstract Number: 1144 • ACR Convergence 2020
Concerns and Behaviors of Patients with Common Autoimmune Rheumatic Diseases in the United States Early in the COVID-19 Pandemic
Michael George¹, Shilpa Venkatachalam², Shubhasree Banerjee¹, Joshua Baker¹, Peter Merkel¹, David Curtis³, Kelly Gavigan⁴, Maria (Maio) Danila⁵, Jeffrey R Curtis⁶ and William Nowell⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, ³Global Healthy Living Foundation, New York City, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham (UAB), Birmingham, AL, ⁶Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Global Healthy Living Foundation, New York City, NY
Background/Purpose: Patients with autoimmune rheumatic diseases may be particularly concerned about COVID-19. We aimed to assess concerns and associated health behaviors of patients with autoimmune…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: 0103 • ACR Convergence 2020
The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative
Rachel Elam¹, Sandeepkumar Gupta², Omar Tolaymat², Sowmya Vasan³, Carolyn Crandall⁴, Jean Wactawski-Wende⁵, Karen Johnson⁶ and Laura Carbone², ¹Augusta University, Evans, GA, ²Augusta University, Augusta, GA, ³WHI, Seattle, WA, ⁴UCLA, Los Angeles, CA, ⁵University of Buffalo, Buffalo, NY, ⁶University of Tennessee Health Sciences Center, Memphis, TN
Background/Purpose: This study was conducted to evaluate the extent to which disease modifying antirheumatic medications (DMARDs) used as part of triple therapy for treatment of…
Abstract Number: 0375 • ACR Convergence 2020
Efficacy of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort
Ashish Mathew¹, Mitchell Sutton², Daniel Pereira², Vinod Chandran³ and Dafna Gladman³, ¹University Health Network, Vellore, Tamil Nadu, India, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is a common clinical feature of psoriatic arthritis (PsA). There is limited evidence on the effect of treatment on enthesitis. Our purpose was…
Abstract Number: 0642 • ACR Convergence 2020
COVID-19 Infection in Rheumatologic Patients on Treatment with Targeted Therapies
Marta González Fernández¹, Orlando Pompei fernández², Joaquín María Belzunegui Otano³, Paula García Escudero¹, Claudia Stoye², Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0869 • ACR Convergence 2020
Retinal Toxicity in a Multinational Inception Cohort of Systemic Lupus Patients on Hydroxychloroquine
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Díaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Barakaldo, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Despite the beneficial effects of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE), retinal toxicity is a concern. Factors associated with retinal toxicity have been…
Abstract Number: 1186 • ACR Convergence 2020
Red Cell Distribution Width and Absolute Lymphocyte Count Associate with Biomarkers of Inflammation and Subsequent Mortality in Rheumatoid Arthritis
Sofi Damjanovska¹, Lenche Kostadinova², Ibtissam Gad³, Sameena Syed⁴, Alyssa Lange⁵, Corinne Kowal⁶, Carey Shive⁷, Christopher Burant⁸, Brigid Wilson⁹, Taissa Bej⁹, Nora Singer¹⁰, David Canaday⁴, Maya Mattar¹¹, David Zidar⁴ and Donald Anthony¹², ¹Case Western Reserve University/Cleveland VA Medical Center, Cleveland Heights, OH, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ³Case Western Reserve/ Cleveland VA Medical Center, Cleveland Heights, OH, ⁴Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁵Cleveland VA Medical Center, Cleveland, ⁶Case western reserve university/Cleveland VA Medical Center, ohio, ⁷(2) Department of Pathology, Case Western Reserve University, ohio, ⁸Case Western Reserve University, Cleveland, ⁹Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ¹⁰The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ¹¹Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ¹²Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Peripheral blood red cell distribution width (RDW) and absolute lymphocyte count (ALC) are associated with aging, cardiovascular disease (CVD), and mortality in the general…
Abstract Number: 1576 • ACR Convergence 2020
Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review
Adam Kilian¹, Yu Pei Eugenia Chock², Irvin Huang³, Elizabeth Graef⁴, Laura Upton⁵, Aneka Khilnani⁶, Sonia Silinsky Krupnikova⁷, Ibrahim Almaghlouth⁸, Laura Cappelli⁹, Ruth Fernandez-Ruiz¹⁰, Brittany Frankel³, Jourdan Frankovich¹¹, Carly Harrison¹², Bharat Kumar¹³, Kanika Monga¹⁴, Jorge Rosario Vega¹¹, Namrata Singh¹⁵, Jeffrey Sparks¹⁶, Elaine Sullo⁶, Kristen Young¹⁷, Ali Duarte-Garcia¹⁸, Michael Putman¹⁹, Sindhu Johnson²⁰, Jean Liew³ and Aruni Jayatilleke²¹, ¹George Washington University, Washington, DC, ²Yale School of Medicine, Greenwich, CT, ³University of Washington, Seattle, WA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Georgetown University School of Medicine, Washington, DC, ⁶The George Washington University School of Medicine and Health Sciences, Washington, DC, ⁷The George Washington University School of Medicine and Health Sciences, Rockville, MD, ⁸King Saud University, Riyadh, Saudi Arabia, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰New York University School of Medicine, New York, ¹¹Temple University, Philadelphia, PA, ¹²Lupus Chat, NA, ¹³University of Iowa Hospitals and Clinics, Iowa City, IA, ¹⁴UT Health Rheumatology, HOUSTON, TX, ¹⁵University of Washington, Bellevue, WA, ¹⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁷University of Texas Southwestern Medical Center, Dallas, TX, ¹⁸Mayo Clinic, Rochester, MN, ¹⁹Northwestern University, Chicago, IL, ²⁰University of Toronto, Toronto, ON, Canada, ²¹Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
Abstract Number: 1841 • ACR Convergence 2020
Outcomes After Hydroxychloroquine Reduction or Discontinuation in a Multinational Inception Cohort of Systemic Lupus
Celline Almeida-Brasil¹, John Hanly², Murray Urowitz³, Ann Clarke⁴, Rosalind Ramsey-Goldman⁵, Caroline Gordon⁶, Michelle Petri⁷, Ellen M Ginzler⁸, Daniel J Wallace⁹, Sang-Cheol Bae¹⁰, Juanita Romero-Diaz¹¹, Mary Ann Dooley¹², Christine A. Peschken¹³, David Isenberg¹⁴, Anisur Rahman¹⁴, Susan Manzi¹⁵, Søren Jacobsen¹⁶, S. Sam Lim¹⁷, Ronald Van Vollenhoven¹⁸, Ola Nived¹⁹, Andreas Jönsen¹⁹, Diane Kamen²⁰, Cynthia Aranow²¹, Guillermo Ruiz-Irastorza²², Jorge Sanchez-Guerrero²³, Dafna Gladman²⁴, Paul Fortin²⁵, Graciela Alarcón²⁶, Joan Merrill²⁷, Kenneth Kalunian²⁸, Manuel Ramos-Casals²⁹, Kristjan Steinsson³⁰, Asad Zoma³¹, Anca Askanase³², Munther Khamashta³³, Ian Bruce³⁴, Murat Inanc³⁵ and Sasha Bernatsky³⁶, ¹McGill University, Montreal, Canada, ²QEII Health Sciences Centre, Halifax, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Calgary, Calgary, Canada, ⁵Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶University of Birmingham, Birmingham, England, United Kingdom, ⁷Johns Hopkins University School of Medicine, Baltimore, ⁸SUNY Downstate Health Sciences University, Brooklyn, ⁹Cedars-Sinai Medical Center, Beverly Hills, CA, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹¹Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico City, Mexico, ¹²UNC Health, Chapel Hil, ¹³University of Manitoba, Winnipeg, Canada, ¹⁴University College London, London, United Kingdom, ¹⁵Temple University, Philadelphia, ¹⁶University of Copenhagen, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸University of Amsterdam, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Medical University of South Carolina, Charleston, SC, ²¹Feinstein Institutes for Medical Research, Manhasset, NY, ²²Hospital Universitario Cruces, Bizkaia, Spain, ²³University of Toronto, Toronto, Canada, ²⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²⁵CHU de Quebec - Universite Laval, Quebec, Canada, ²⁶Division of Clinical Immunology and Rheumatology, Department of Medicine, School of Medicine, The University of Alabama at Birmingham; Department of Medicine, School of Medicine; Universidad Peruana Cayetano, Heredia, Alabama, ²⁷New York University, New York, ²⁸University of California San Diego, La Jolla, CA, ²⁹University of Barcelona, Barcelona, Spain, ³⁰Reykjavik University, Reykjavik, Iceland, ³¹University of Glasgow, Glasgow, United Kingdom, ³²Columbia University College of Physicians & Surgeons, New York, NY, ³³King's College London, London, United Kingdom, ³⁴The University of Manchester, Manchester, United Kingdom, ³⁵Department of Rheumatology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ³⁶The Research Institute of the McGill University Health Centre, Montreal, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone treatment for several autoimmune diseases including Systemic Lupus Erythematosus (SLE). Recently, concerns arose regarding HCQ shortages for SLE patients,…
Abstract Number: 0136 • ACR Convergence 2020
Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
Clifton Bingham III¹, David Walker², Peter Nash³, Susan Lee⁴, Lei Ye⁴, Hao Hu⁴, Javaria Mona Khalid⁵ and Bernard Combe⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶University of Montpellier, Montpellier, France
Background/Purpose: Reduction in pain and fatigue, maintenance of physical functioning, and improvement in health-related quality of life (HRQoL) are vital aspects of successful treatment for…
Abstract Number: 0377 • ACR Convergence 2020
Evaluation of Sex Differences in the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis: A Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials
Lihi Eder¹, Dafna Gladman², Sibel Zehra Aydin³, Alexis Ogdie⁴, Harry Shi⁵, Pierre-Alexandre Landry⁶ and Rayana Luna⁶, ¹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada, ⁴Division of Rheumatology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Canada ULC, Kirkland, Canada
Background/Purpose: Studies indicate that sex (male vs female) is predictive of outcomes with PsA treatments, such as TNF inhibitors (TNFi).1 Tofacitinib is an oral JAK…
Abstract Number: 0715 • ACR Convergence 2020
JIA-ACR50 Response as a Predictor of Minimal Disease Activity in Patients Aged 2–17 Years with Polyarticular-Course JIA Treated with SC Abatacept
Nicolino Ruperto¹, Hermine I Brunner², Alberto Berman³, Francisco Ávila-Zapata⁴, Gerd Horneff⁵, Maria Alessio⁶, Mara Becker⁷, Alexandre Belot⁸, Ruben Burgos-Vargas⁹, Alina Boteanu¹⁰, Claudia Goldenstein-Schainberg¹¹, Iloite Scheibel¹², Maria Teresa Terreri¹³, Lawrence Zemel¹⁴, Robert Wong¹⁵, Margarita Askelson¹⁵, Marleen Nys¹⁶, Alberto Martini¹⁷ and Daniel J Lovell², ¹Istituto Giannina Gaslini, Genova, Italy, ²PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Universidad Nacional de Tucumán and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁴Star Medica Hospital, Merida, Yucatan, Mexico, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Università di Napoli Federico II, Naples, Italy, ⁷Duke University School of Medicine, Durham, NC, ⁸Centre Hospitalier Universitaire de Lyon, Lyon, France, ⁹Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ¹⁰Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹¹University of São Paulo, São Paulo, Brazil, ¹²Hospital Criança Conceição, Porto Alegre, Brazil, ¹³Federal University of São Paulo, São Paulo, Brazil, ¹⁴Connecticut Children’s Medical Center, Hartford, CT, ¹⁵Bristol-Myers Squibb Company, Princeton, NJ, ¹⁶Bristol-Myers Squibb Company, Braine-L’Alleud, Belgium, ¹⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Effectiveness of SC abatacept in patients with polyarticular-course JIA (pJIA) was shown in a 2-year, open-label Phase III international study (NCT01844518). Here we assess…
Abstract Number: 0871 • ACR Convergence 2020
Hydroxychloroquine Dose Reduction and SLE Flares
April Jorge¹, Gary Ho², Michael Wu², Karen Costenbader³ and Hyon Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: 2016 ophthalmology guidelines recommend using hydroxychloroquine (HCQ) dosages < 5mg/kg/day, which is lower than the traditional 400mg/day for the majority of SLE patients. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].